We found no difference regarding age, primary tumour location, time of metastases (synchronous vs metachronous), resection of primary tumour or received adjuvant chemotherapy between patients, which were treated with or without a BRAF inhibitor (Suppl. This evidence concerns the gene BRAF and neoplasm.